Does Pfizer have too much debt?

Pfizer Financial Health and Debt Levels

When evaluating major pharmaceutical corporations like Pfizer Inc, questions regarding corporate debt and long-term stability frequently arise, especially given large-scale acquisitions and changing market demands.

As of the latest financial reporting, Pfizer carries a total debt of 60.6 billion USD. While this figure sounds substantial to individual investors, corporate balance sheets of this scale must be evaluated in the context of global revenues and total assets.

Financial models and solvency metrics indicate that Pfizer's probability of bankruptcy sits at just 1.2%. This exceptionally low percentage demonstrates that a financial collapse or structural failure is highly unlikely, confirming that the pharmaceutical giant maintains strong underlying stability despite its debt obligations.